Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Portfolio Pulse from
Indaptus Therapeutics presented promising interim safety data from its Phase 1 clinical trial of Decoy20 at the SITC 2024 Annual Meeting. The data showed positive safety, pharmacokinetics, and biomarker results from two cohorts of single administration and one cohort of weekly administration.
November 07, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics reported encouraging interim safety data from its Phase 1 trial of Decoy20, showing positive results in safety, pharmacokinetics, and biomarkers.
The positive interim safety data from the Phase 1 trial of Decoy20 is likely to boost investor confidence in Indaptus Therapeutics, potentially leading to a short-term increase in stock price. The data presented at a reputable conference like SITC adds credibility and visibility to the company's research efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100